用SELDI技术预测吉非替尼疗效的前瞻性研究报告.docVIP

用SELDI技术预测吉非替尼治疗肺癌疗效的前瞻性研究报告 谢莉1 马小军2 魏淑青3 李琦1 李波3 裴毅3( 1.山西医科大学第二临床医学院，太原 030001 2. 山西省大同市第五人民医院呼吸内科，大同 037006 (3. 山西省肿瘤医院老年病科，太原 030013 摘要：目的 介绍SELDI-TOF-MS技术预测吉非替尼治疗肺癌疗效观察，探索新的用药指征。方法 应用CM10弱阳离子芯片结合表面增强飞行时间质谱（SELDI-TOF-MS）技术检测9例晚期肺癌患者口服吉非替尼前血清样本的蛋白质谱，口服吉非替尼1个月后，根据实体瘤近期疗效标准分为服药有效组（CR+PR）（4例）和无效组（SD+PD）（5例），利用Biomarker Wizard软件比较各组间的血清蛋白质指纹图谱。结果 有效组与无效组相比有4个蛋白质峰有显著差异性，M/Z分别为4889，1576，1762和8693，与无效组相比，有效组上调的峰为2个，其M/Z为1576和1762，下调的峰为2个，其M/Z为4889和8693。结论 SELDI-TOF-MS技术用于肺癌患者吉非替尼治疗前血清蛋白质质谱分析，可筛选出预测吉非替尼治疗疗效的相关蛋白质组指纹，此方法捕获的蛋白质组指纹，可作为一种选择用药的新指标。其他抗肿瘤药物的预测也可由此效仿。 关键词：SELDI-TOF-MS；吉非替尼；肺癌；疗效 中图分类号：R393 文献标识码：A 文章编号：4912 A report on the study of the estimation of the therapeutic effect in treatment of lung cancer with gefitinib by SELDI ＊ 研究报告吉非替尼的SELDI 在肺癌治疗的效果 Xie Li1, Ma Xiao-jun2, Weishuqing,3 Li Qi1, Li Bo3, PEI Yi3△ 1. The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, 030001,Shan Xi, China 2. Da Tong City Fifth People’s Hospital, Da Tong, 037006, Shan Xi, China △3. Shan Xi Tumor Hospital, Taiyuan, 030013,Shan Xi, China Abstract：Objective Introduce a new technology on prediction of the therapeutic effect in treatment of 1ung cancer with Gefitinib, and a new indicator in application of anti-tumor drugs. Method The serum of 9 advance lung cancer were collected before application of Gefitinib, and by SELDI-TOF-MS(surface-enhanced laser desorption/ionization time-of-flight mass spectrometry) technique and CM10 proteinchip, these serum proteomic fingerprints were memorized. According to the Response Evaluation Criteria In Solid Tumor(WHO,1979), 9 patients who had took Gefitinib for 1 month were divided into 2 groups, efficacy group(4 cases, CR+PR) and inefficacy group(5 cases , SD+PD). The detected data were analyzed by Biomarker Wizard Software. Results There were 4 significant different protein fingerprints between efficacy and ineffiecacy group (M/Z values were 4889，1576，1762 and 8693). Compared with inefficacy group,it was height that